Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
13F holders, Q4 2025
Institutional positions in Adma Biologics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 357
- −2 vs. Q3 2025
- Shares held
- 220.4M
- +1.11M (+0.5%) vs. Q3 2025
- Total value
- $4.02B
- +$740.6M (+22.6%) vs. Q3 2025
- New holders
- 59
- 140 more added
- Sold out
- 61
- 119 more reduced
7 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADMA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 322 | $1.70B |
| Q1 2026 | 358 | $1.91B |
| Q4 2025 | 357 | $4.02B |
| Q3 2025 | 366 | $3.28B |
| Q2 2025 | 369 | $3.84B |
| Q1 2025 | 347 | $4.07B |
| Q4 2024 | 321 | $3.50B |
| Q3 2024 | 306 | $4.16B |
| Q2 2024 | 253 | $2.03B |
| Q1 2024 | 214 | $1.16B |
| Q4 2023 | 184 | $764.6M |
| Q3 2023 | 188 | $612.7M |
| Q2 2023 | 179 | $610.6M |
| Q1 2023 | 163 | $547.2M |
| Q4 2022 | 160 | $592.2M |
| Q3 2022 | 130 | $315.4M |
| Q2 2022 | 113 | $236.0M |
| Q1 2022 | 105 | $189.9M |
| Q4 2021 | 88 | $137.1M |
| Q3 2021 | 72 | $47.3M |
| Q2 2021 | 90 | $68.6M |
| Q1 2021 | 104 | $85.4M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Adma Biologics, Inc.; share changes are against Q3 2025.